ANN as a prognostic tool after treatment of non-seminoma testicular cancer

Central European Journal of Medicine - Tập 7 - Trang 672-679 - 2012
Michał P. Marszałł1, Jerzy Krysiński2, Wiktor D. Sroka1, Zbigniew Nyczak3, Marek Stefanowicz4, Tomasz Waśniewski4, Jerzy Romaszko5, Adam Buciński6
1Department of Medicinal Chemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Bydgoszcz, Poland
2Department of Marketing and Pharmaceutical Law, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Bydgoszcz, Poland
3The WCO Greater Poland Cancer Centre, Poznan, Poland
4Gynaecology, Obstetrics and Gynaecological Oncology Ward, Provincial Specialist Hospital in Olsztyn, Olsztyn, Poland
5NZOZ Pantamed Sp z o.o. in Olsztyn, Olsztyn, Poland
6Department of Biopharmacy, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

Tóm tắt

Testicular cancer is rare but is the most common cancer in males between 15 and 34 years of age. Two principal types of testicular cancer are distinguished: seminomas and non-seminomas. If detected early, the overall cure rate for testicular cancer exceeds 90%. In this study, artificial neural network (ANN) analysis as a prognostic tool was demonstrated regard to five year recurrence after the non-seminoma treatment. Data from 202 patients treated for non-seminoma were available for evaluation and comparison. A total of 32 variables were analysed using the ANN. The ANN approach, as an advanced multivariate data processing method, was demon-strated to provide objective prognostic data. Some of these prognostic factors are consistent or even imperceptible with previously evaluated by other statistical methods.

Tài liệu tham khảo

Masters J.R.W., Köberle B., Curing metastatic cancer: lessons from testicular germ-cell tumors, Nat. Rev. Cancer, 2003, 3, 517–525 Hameed A., White B., Chinegwundoh F., Thwaini A., Pahuja A., A review in management of testicular cancer: single center review, World Journal of Oncology, 2011, 2, 94–101 Schmelz H.U., Port M., Hauck E.W., Schwerer M.J., Weidner W., Sparwasser Ch., Abend M., Apoptosis: a key effector mechanism of lymphocyte action in human nonseminomatous testicular carcinoma? BJU International, 2005, 96, 158–163 Aschim E.L, Haugen T.B., Tretli S., Daltveit A.K., Grotmol T. Risk factors for testicular cancer — differences between pure non-seminoma and mixed seminoma/non-seminoma?, INT. J. ANDROL., 2006, 29, 458–467 Robertson A.G., Read G., The value of lactate dehydrogenase as a nonspecific tumour marker for seminoma of the testis, Br. J. Cancer, 1982, 46, 994 Testis. In: Edge S.B., Byrd D.R., Compton C.C., et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, 469–478 Daugaard G., Petersen P.M., Rorth M., Surveillance in stage I testicular cancer, APMIS, 2003, 111, 76–85 Fossa S.D., Chen J., Schonfeld S.J., McGlynn K.A., McMaster M.L., Gail M.H., Travis L.B., Risk of contralateral testicular cancer: a population based study of 29515 U.S. men, J. Natl. Caner. Inst., 2005 97, 1056–1066 Bray F., Ferlay Devesa S.S., McGlynn K.A., øller H., Interpreting the international trends in testicular seminoma and nonseminoma incidence, Nat. Clin. Pract. Urol., 2006, 3, 532–543 Bradburn M.J., Clark T.G., Love S.B., Altman D.G., Survival analysis part II: Multivariate data analysis — an introduction to concepts and methods, Br. J. Cancer., 2003, 89, 431–436 Niederberger C.S., Commentary on the use of neuronal networks in clinical urology, J. Urol., 1995, 153, 1362 Cai T., Conti G., Lorenzini M., Bartoletti R., Artificial intelligences in urological practice: the key to success?, Ann. Oncol., 2007, 18, 604–605 Abbod M.F., Catto J.W.F., Linkens D.A., Hamdy F.C., Application of artificial intelligence to the management of urological cancer, J. Urol., 2007, 178, 1150–1156 Schwarzer G., Schumacher M., Artificial neural networks for diagnosis and prognosis in prostate cancer, Semin. Urol. Oncol., 2002, 20, 89–95 Schwarzer G., Vach W., Schumacher M., On the misuses of artificial neural networks for prognostic and diagnostic classification in oncology, Stat. Med., 2002, 19, 541–561 Clark T.G., Bradburn M.J., Love S.B., Altman D.G., Survival analysis part IV: Further concepts and methods in survival analysis, Br. J. Cancer, 2003, 89, 781–786 Sargent D.J., Comparison of artificial neural networks with other statistical approaches: results from medical data sets, Cancer, 2001, 91, 1636–1642 Bączek T., Buciński A., Ivanov A.R., Kaliszan R., Artificial neural network analysis for evaluation of peptide MS/MS spectra in proteomics, Anal. Chem., 2004, 76, 1726–1732 Buciński A., Markuszewski M.J., Wiktorowicz W., Krysiński J., Kaliszan R., Artificial neural networks for prediction of antibacterial activity in series of imidazole derivatives, Comb. Chem. High Throughpu. Screen, 2004, 7, 327–336 Buciński A., Nasal A., Kaliszan R., Pharmacological classification of drugs based on neural network processing of molecular modeling data, Comb. Chem. High Throughput Screen, 2000, 3, 525–533 Moul J.W., Snow P.B., Fernandez B., Maher P.D., Sesterhenn I.A., Neural Network Analysis of quantitative histological factors to predict pathological stage in clinical stage I nonseminomatous testicular cancer, J. Urol., 1995, 153, 1674–1677 Samili M.M., Dogan I., An artificial neural network for predicting the presence of spermatozoa in the testes of men with nonobstructive azoospermia, J. Urol., 2004, 171, 2354–2357 Snow P.B., Rodvold D.M., Brandt J.M., Artificial neural networks in clinical urology, Urology, 1999, 54, 787–790 Wei T.J., Tewari A., Artificial neural networks in urology: PRO, Urology, 1995, 54, 945–948 Djavan B., Remzi M., Zlotta A., Seitz C., Snow P., Marberger M., Novel artificial neural network for early detection of prostate cancer, J. Clin. Oncol., 2002, 20, 921–929 Snow P.B., Smith D.S., Catalona W.J., Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study, J. Urol., 1994, 152, 1923–1926 Tawari A. Narayan, P., Novel staging tool for localized prostate cancer: a pilot study using genetic neural network, J. Urol., 1998, 160, 443–444 Feleppa E.J., Ennis R.D., Schiff P.B., Wuu C.S., Kalisz A., Ketterling J., Urban S., Liu T., Fair W.R., Porter C.R., Gillespie J.R., Ultrasonic spectrum-analysis and neural-network classification as a basis for ultrasonic imaging to target brachytherapy of prostate cancer, Brachytherapy, 2002, 1, 48–53. Prater J.S., Richard W.D. Segmenting ultrasound images of the prostate using neural networks, Ultrason. Imag.,1992, 4, 159–185 Han M., Snow P.B., Brandt J.M., Partin A.W., Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma, Cancer, 2001, 91, 1661–1666 Khan J., Wei J.S., Ringner M., Saal L.H., Ladanyi M., Wastermann F., Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat. Med., 2001, 7, 673–679 Wells D.M., Niederer, J., A medical expert system approach using artificial neural networks for standardized treatment planning, Int. J. Radiat. Oncol. Biol. Phys., 1998, 41, 173–182